Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues

Ayşe Koçak; Meliha Koldemir Gündüz; Güllü Kaymak; Elif Aydın

Makale detayları

Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues

Yazarlar:

Ayşe Koçak | Meliha Koldemir Gündüz | Güllü Kaymak | Elif Aydın

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.37 Issue 1, pp.72-79

Belge Tipi:

Makale

Yayın Tarihi:

1/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001302666

pISSN:

1019-1941

Anahtar kelimeler:

Özet:

 Objective: Scleroderma SSc is a rare autoimmune tissue disease. There is currently no effective treatment for SSc. The aim of this study was to investigate the antioxidant and anti-inflammatory effects of upadacitinib and PD29 on total oxidant status TOS, total antioxidant status TAS, malondialdehyde MDA, catalase CAT, glutathione GSH peroxidase levels, and interleukin-6 IL-6 and interleukin-13  IL-13 in kidney tissues of an experimental SSc model. Materials and Methods: The experimental design was established with five groups of eight mice: Control, bleomycin BLM 5 μgkg, BLM  upadacitinib 3mgkg, BLM  PD29 5 mgkg and BLM  PD29  upadacitinib group. BLM was administered subcutaneously once a day for 21 days. PD29 was administered subcutaneously and upadacitinib gavage were injected for 21 days. Renal tissues were collected at the end of the experiment. Renal TOS, TAS, MDA, CAT, GSH levels, and IL-6 and IL-13 gene expressions were evaluated. Results: Upadacitinib and PD29 affected oxidant status and TOS. MDA levels decreased, and GSH, CAT, and TAS levels increased. Also, upadacitinib and PD29 decreased inflammation via IL-6 and IL-13 cytokines. Conclusion: Upadacitinib and PD29 may have therapeutic roles for SSc renal crisis.

 Objective: Scleroderma SSc is a rare autoimmune tissue disease. There is currently no effective treatment for SSc. The aim of this study was to investigate the antioxidant and anti-inflammatory effects of upadacitinib and PD29 on total oxidant status TOS, total antioxidant status TAS, malondialdehyde MDA, catalase CAT, glutathione GSH peroxidase levels, and interleukin-6 IL-6 and interleukin-13  IL-13 in kidney tissues of an experimental SSc model. Materials and Methods: The experimental design was established with five groups of eight mice: Control, bleomycin BLM 5 μgkg, BLM  upadacitinib 3mgkg, BLM  PD29 5 mgkg and BLM  PD29  upadacitinib group. BLM was administered subcutaneously once a day for 21 days. PD29 was administered subcutaneously and upadacitinib gavage were injected for 21 days. Renal tissues were collected at the end of the experiment. Renal TOS, TAS, MDA, CAT, GSH levels, and IL-6 and IL-13 gene expressions were evaluated. Results: Upadacitinib and PD29 affected oxidant status and TOS. MDA levels decreased, and GSH, CAT, and TAS levels increased. Also, upadacitinib and PD29 decreased inflammation via IL-6 and IL-13 cytokines. Conclusion: Upadacitinib and PD29 may have therapeutic roles for SSc renal crisis.

 Objective: Scleroderma SSc is a rare autoimmune tissue disease. There is currently no effective treatment for SSc. The aim of this study was to investigate the antioxidant and anti-inflammatory effects of upadacitinib and PD29 on total oxidant status TOS, total antioxidant status TAS, malondialdehyde MDA, catalase CAT, glutathione GSH peroxidase levels, and interleukin-6 IL-6 and interleukin-13  IL-13 in kidney tissues of an experimental SSc model. Materials and Methods: The experimental design was established with five groups of eight mice: Control, bleomycin BLM 5 μgkg, BLM  upadacitinib 3mgkg, BLM  PD29 5 mgkg and BLM  PD29  upadacitinib group. BLM was administered subcutaneously once a day for 21 days. PD29 was administered subcutaneously and upadacitinib gavage were injected for 21 days. Renal tissues were collected at the end of the experiment. Renal TOS, TAS, MDA, CAT, GSH levels, and IL-6 and IL-13 gene expressions were evaluated. Results: Upadacitinib and PD29 affected oxidant status and TOS. MDA levels decreased, and GSH, CAT, and TAS levels increased. Also, upadacitinib and PD29 decreased inflammation via IL-6 and IL-13 cytokines. Conclusion: Upadacitinib and PD29 may have therapeutic roles for SSc renal crisis.

 Objective: Scleroderma SSc is a rare autoimmune tissue disease. There is currently no effective treatment for SSc. The aim of this study was to investigate the antioxidant and anti-inflammatory effects of upadacitinib and PD29 on total oxidant status TOS, total antioxidant status TAS, malondialdehyde MDA, catalase CAT, glutathione GSH peroxidase levels, and interleukin-6 IL-6 and interleukin-13  IL-13 in kidney tissues of an experimental SSc model. Materials and Methods: The experimental design was established with five groups of eight mice: Control, bleomycin BLM 5 μgkg, BLM  upadacitinib 3mgkg, BLM  PD29 5 mgkg and BLM  PD29  upadacitinib group. BLM was administered subcutaneously once a day for 21 days. PD29 was administered subcutaneously and upadacitinib gavage were injected for 21 days. Renal tissues were collected at the end of the experiment. Renal TOS, TAS, MDA, CAT, GSH levels, and IL-6 and IL-13 gene expressions were evaluated. Results: Upadacitinib and PD29 affected oxidant status and TOS. MDA levels decreased, and GSH, CAT, and TAS levels increased. Also, upadacitinib and PD29 decreased inflammation via IL-6 and IL-13 cytokines. Conclusion: Upadacitinib and PD29 may have therapeutic roles for SSc renal crisis.

Makale detayları

Effects of upadacitinib and PD29 on oxidative damage and inflammation in bleomycin-induced scleroderma model kidney tissues

Yazarlar: Ayşe Koçak | Meliha Koldemir Gündüz | Güllü Kaymak | Elif Aydın

Yayıncı: Marmara University

Ana Başlıklar: Surgery (Other)

Dergi: Marmara Medical Journal Vol.37 Issue 1, pp.72-79

Belge Tipi: Makale

Yayın Tarihi: 1/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001302666

pISSN: 1019-1941

Scleroderma

Upadacitinib

PD29

Renal tissue

Sayı

Yazarlar:

Ayşe Koçak | Meliha Koldemir Gündüz | Güllü Kaymak | Elif Aydın

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.37 Issue 1, pp.72-79

Belge Tipi:

Makale

Yayın Tarihi:

1/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001302666

pISSN:

1019-1941